Surmodics, Inc.

NasdaqGS:SRDX Stock Report

Market Cap: US$487.5m

Surmodics Management

Management criteria checks 2/4

Surmodics' CEO is Gary Maharaj, appointed in Dec 2010, has a tenure of 14.17 years. total yearly compensation is $3.67M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 1.34% of the company’s shares, worth $6.55M. The average tenure of the management team and the board of directors is 6.8 years and 14.2 years respectively.

Key information

Gary Maharaj

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage17.7%
CEO tenure14.2yrs
CEO ownership1.3%
Management average tenure6.8yrs
Board average tenure14.2yrs

Recent management updates

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03
Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 30
Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

May 02
Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Sep 17
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26
News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22
An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14
Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17
Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03
Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08
Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22
Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03
Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04
Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24
Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

CEO Compensation Analysis

How has Gary Maharaj's remuneration changed compared to Surmodics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$14m

Sep 30 2024US$4mUS$647k

-US$12m

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

US$14m

Dec 31 2023n/an/a

US$6m

Sep 30 2023US$4mUS$640k

-US$2m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$36m

Dec 31 2022n/an/a

-US$32m

Sep 30 2022US$3mUS$620k

-US$27m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021n/an/a

US$2m

Sep 30 2021US$3mUS$602k

US$4m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

US$7m

Dec 31 2020n/an/a

US$701k

Sep 30 2020US$3mUS$585k

US$1m

Jun 30 2020n/an/a

US$8m

Mar 31 2020n/an/a

US$7m

Dec 31 2019n/an/a

US$6m

Sep 30 2019US$2mUS$568k

US$8m

Jun 30 2019n/an/a

US$2m

Mar 31 2019n/an/a

-US$2m

Dec 31 2018n/an/a

-US$2m

Sep 30 2018US$2mUS$551k

-US$4m

Compensation vs Market: Gary's total compensation ($USD3.67M) is above average for companies of similar size in the US market ($USD2.12M).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.

CEO

Gary Maharaj (61 yo)

14.2yrs

Tenure

US$3,665,496

Compensation

Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...

Leadership Team

NamePositionTenureCompensationOwnership
Gary Maharaj
CEO, President & Director14.2yrsUS$3.67m1.34%
$ 6.5m
Timothy Arens
Senior VP of Finance & Information Technology and CFO6.8yrsUS$1.34m0.47%
$ 2.3m
Gordon Weber
Senior VP of Legal4.8yrsUS$1.15m0.15%
$ 717.4k
Charles Olson
Senior VP & President of Medical Device Coatings20.3yrsUS$1.13m0.37%
$ 1.8m
Teryl L. Sides
Senior VP & President of Vascular Interventions2.8yrsUS$1.52m0.24%
$ 1.2m
John Manders
Corporate Controller6.8yrsno data0.057%
$ 278.1k
Joel Suiter
Director of Corporate Developmentno datano datano data
Joseph Stich
Senior VP of Human Resources & President of In Vitro Diagnostics4.8yrsUS$970.92k0.43%
$ 2.1m

6.8yrs

Average Tenure

59yo

Average Age

Experienced Management: SRDX's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gary Maharaj
CEO, President & Director14.2yrsUS$3.67m1.34%
$ 6.5m
David Dantzker
Independent Director14.1yrsUS$185.00k0.27%
$ 1.3m
Susan Knight
Independent Non-Executive Chair of the Board17.1yrsUS$234.00k0.14%
$ 680.4k
José Bedoya
Independent Director23.1yrsUS$176.50k0.20%
$ 987.4k
Lisa Heine
Independent Director7.8yrsUS$181.50k0.094%
$ 458.7k

14.2yrs

Average Tenure

68yo

Average Age

Experienced Board: SRDX's board of directors are seasoned and experienced ( 14.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 10:43
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Surmodics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Daniel OwczarskiAvondale Partners
Michael PetuskyBarrington Research Associates, Inc.